

IN THE CLAIMS

Please amend the claims as follows:

Claim 1-2. (Cancelled)

Claim 3. (Previously Presented) Sodium trans-4-[1-[2,5-dichloro-4-[(1-methyl-1H-3-indolylcarbonyl)amino]phenylacetyl]-(4S)-methoxy(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylate pentahydrate, which is in the form of plate-like crystals.

Claim 4. (Previously Presented) Sodium trans-4-[1-[2,5-dichloro-4-[(1-methyl-1H-3-indolylcarbonyl)amino]phenylacetyl]-(4S)-methoxy(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylate pentahydrate, which is in the form of Type-II crystals having the full XRD pattern of FIG. 4.

Claims 5-17 (Cancelled).

Claim 18 (Currently Amended) A medicine containing, as an active ingredient, a compound as described in claim 4 and wherein the medicine is in a form ~~selected from the group consisting of a tablet, powder, granule, and capsule.~~

Claim 19 (Cancelled).